Dihexa for Alzheimer's: What the Research Shows | telos rx
Laptop, coffee mug and handwritten notes on a wooden desk, a calm setting for reading the Dihexa Alzheimer's research
← Back to blog
cognitive peptides

Dihexa for Alzheimer's: What the Research Shows

By TelosRX Editorial Team

The research on Dihexa for Alzheimer's is promising in rodents and missing in humans. Animal studies show synapse growth and memory gains. No human Dihexa trials exist, and a related compound failed its trial. TelosRX breaks down the evidence.

Search "Dihexa" and you'll find bold claims. "Rebuilds brain connections." "Stronger than BDNF." Some sellers all but promise a fix for memory loss.

The real story is more interesting, and more cautious. This review walks through what the published studies on Dihexa for Alzheimer's actually found. Every finding below is cited. None of it is a promise of results in people.

One ground rule first: Dihexa is not FDA-approved for any use. It has never been tested in a published human trial. Everything here is research context, not a recommendation.

What Is Dihexa, in Plain English?

Dihexa is a small, lab-made molecule. It's built from a fragment of angiotensin IV, a peptide involved in blood pressure signaling. Researchers at Washington State University modified that fragment to make it stable and able to reach the brain.

Technically, it's a peptidomimetic (a molecule that mimics a peptide). Most people still call it a peptide. Its claimed target is the HGF/MET system. HGF stands for hepatocyte growth factor, a protein that helps cells grow and connect. MET is its receptor.

In the brain, HGF/MET signaling supports synapses, the junctions where neurons talk to each other. Synapse loss tracks closely with memory decline in Alzheimer's disease. That's why this pathway caught researchers' attention.

Why Researchers Looked at Dihexa for Alzheimer's

Most Alzheimer's drug development has targeted amyloid plaques or tau tangles. Dihexa's backers took a different angle. Instead of clearing damage, could a drug help the brain rebuild connections?

A 2015 review in the Journal of Alzheimer's Disease by Wright and Harding laid out that case. The authors argued the brain's HGF/MET system was an untapped target for dementia research. It's an appealing idea. But appealing ideas need human data, and that's where things get thin.

Finding 1: Dihexa Improved Memory in Impaired Rats (2013)

The first major paper came from McCoy and colleagues in the Journal of Pharmacology and Experimental Therapeutics. You can read the 2013 McCoy study abstract on PubMed.

The team gave Dihexa to rats with memory problems. Some rats were impaired with scopolamine, a drug that blocks a key memory chemical. Others were simply old. Memory was tested in a water maze, where rats learn to find a hidden platform.

  • Dihexa-treated rats found the platform faster than impaired controls.
  • The effect appeared with both oral and injected dosing.
  • In cell cultures, Dihexa encouraged new dendritic spines (tiny synapse-bearing branches) at very low concentrations.

What it means: this is a real, peer-reviewed signal. But scopolamine-induced amnesia is not Alzheimer's disease. It's a short-term chemical model. Many drugs that pass it never help people.

Finding 2: The Effects Depended on HGF/MET (2014)

A follow-up by Benoist and colleagues, also in the Journal of Pharmacology and Experimental Therapeutics, asked how Dihexa works. The answer pointed squarely at HGF/MET.

When researchers blocked the MET receptor, Dihexa's effects on synapses and memory faded. The study also reported that Dihexa binds HGF and helps it activate MET.

What it means: this gives Dihexa a plausible mechanism. It also raises a safety flag, which we'll cover below. MET signaling isn't only about synapses.

Finding 3: Gains in an Alzheimer's Mouse Model (2021)

The closest thing to Alzheimer's-specific evidence is a 2021 study in Brain Sciences. Researchers tested Dihexa in APP/PS1 mice. These mice are bred to build up amyloid, a hallmark of Alzheimer's. The full paper is free: AngIV-Analog Dihexa Rescues Cognitive Impairment in the APP/PS1 Mouse.

Here's what the authors reported:

  • Better spatial learning and memory in water-maze testing.
  • More surviving neurons and more synaptophysin, a synapse marker.
  • Lower markers of brain inflammation.
  • Activation of the PI3K/AKT pathway, which helps cells survive stress.

What it means: it's the strongest disease-model data for Dihexa. Still, it's one study in one mouse strain from one group. Mouse models of Alzheimer's have a long record of not predicting human results.

Finding 4: Not Every Animal Study Was Positive (2024)

Good evidence reviews include the misses. A 2024 study in the Journal of Huntington's Disease by Wells and colleagues tested Dihexa in rats. The rats had Huntington's-like damage caused by a mitochondrial toxin.

Dihexa did not protect them. The rats still showed weight, motor and memory deficits. The authors concluded it may not be effective in that model.

What it means: Huntington's isn't Alzheimer's. But this result is a reminder. Dihexa isn't a universal brain-repair molecule, whatever the marketing says.

Finding 5: A Related HGF/MET Drug Missed in Human Trials

This is the most important finding, and the one sellers rarely mention. Dihexa itself never reached clinical trials. But a related compound did.

Fosgonimeton (ATH-1017) is a small-molecule HGF/MET positive modulator developed by Athira Pharma. It comes from the same line of research as Dihexa. If the HGF/MET idea was going to work in people, this was the test.

The LIFT-AD trial was a randomized, placebo-controlled phase 2/3 study. You can find it on ClinicalTrials.gov (NCT04488419). Results were published in 2025 by Porsteinsson and colleagues in the Journal of Alzheimer's Disease Reports.

  • The primary analysis included 287 people with mild-to-moderate Alzheimer's.
  • They received daily under-the-skin injections of fosgonimeton or placebo for 26 weeks.
  • The trial did not meet its primary endpoint, a combined score of thinking and daily function.
  • It also missed its secondary endpoints. Differences that favored the drug were small and not statistically significant.

An earlier phase 2 trial of the same compound, ACT-AD, also missed its primary endpoint.

What it means: fosgonimeton and Dihexa are different molecules. One drug's failure doesn't automatically doom the other. But it's the best human evidence on this pathway so far, and it was disappointing.

Evidence Summary: Dihexa and the HGF/MET Pathway

Study Model Main finding Evidence level
McCoy et al., 2013 Scopolamine-impaired and aged rats; cell cultures Better water-maze memory; new dendritic spines Preclinical
Benoist et al., 2014 Rats; cell cultures Effects depended on MET receptor activation Preclinical (mechanism)
Sun et al., 2021 APP/PS1 Alzheimer's mice Better memory, more neurons, less inflammation Preclinical (disease model)
Wells et al., 2024 Huntington's-like rat model No protective effect Preclinical (negative)
LIFT-AD, 2025 (fosgonimeton) 287 people with mild-to-moderate Alzheimer's Missed primary and secondary endpoints Human RCT, related compound
Dihexa in humans None published No efficacy or safety data No evidence

Why Mouse Results Often Don't Carry Over to People

It's tempting to read "rescued memory in mice" as "will help Grandma." The track record says otherwise. Alzheimer's drug development has one of the highest failure rates in medicine.

There are a few reasons. Mouse models usually copy one feature of the disease, like amyloid buildup. Human Alzheimer's involves amyloid, tau, inflammation, blood vessels and decades of slow change.

  • Timing: mice are often dosed early, before damage is advanced.
  • Simple tests: a water maze measures one narrow kind of memory.
  • Small groups: animal studies often use a handful of animals per group.
  • Dose scaling: a mouse dose doesn't convert neatly to a human dose.

None of this makes the Dihexa studies worthless. It just puts them in their proper place: early-stage evidence that justifies human trials, not a substitute for them.

What We Still Don't Know

The gaps are bigger than the findings. Here's what's missing for Dihexa specifically.

  • Human dosing: no study has set a safe or effective human dose.
  • Human safety: there's no published data on side effects in people.
  • Long-term effects: animal studies ran for weeks, not years.
  • Drug interactions: none have been studied.
  • Pharmacokinetics: data on how it's absorbed and cleared come mostly from rats. One rat serum study reported a half-life of about 335 minutes.

The Alzheimer's Drug Discovery Foundation's cognitive vitality review reached the same conclusion. It noted Dihexa has only been studied in rodents and cell culture, with no ongoing clinical trials.

The Safety Question Nobody Can Answer Yet

Remember Finding 2? Dihexa appears to work by boosting MET signaling. MET is also a well-known growth signal in some cancers. Researchers developing cancer drugs often try to block it.

That doesn't prove Dihexa raises cancer risk. No study has shown that. But it's a theoretical concern that only long-term human data could settle. Right now, that data doesn't exist.

There's also a sourcing problem. Most Dihexa sold online is labeled "for research use only." These products aren't made for people and aren't reviewed for purity or dose accuracy. Our Dihexa safety and side effects review covers these risks in more depth.

How to Read Dihexa Claims Online

You'll see confident posts about Dihexa for Alzheimer's, focus and memory. Run each claim through these questions.

  1. Was it tested in people? For Dihexa, the answer is no.
  2. Which model? A scopolamine rat isn't a person with dementia.
  3. Who's making the claim? Sellers have an obvious incentive.
  4. Are negative results mentioned? If LIFT-AD is missing, the source is cherry-picking.
  5. Is a dose suggested? Any human "dose" for Dihexa is a guess.

Want the mechanism side in more detail? Our earlier review of Dihexa and synaptic plasticity research goes deeper into the cell studies.

How Dihexa Compares With Other Alzheimer's Research Paths

For context, other drug classes are being studied for brain health too. GLP-1 medications are one example. Researchers have asked whether semaglutide affects Alzheimer's risk or progression.

Those questions have large human trials behind them, with mixed results so far. See our review of semaglutide and Alzheimer's research. The contrast is useful. Some ideas have human data that disappointed. Dihexa doesn't have human data at all yet.

FDA-approved Alzheimer's medications do exist, including anti-amyloid antibodies and older symptom-focused drugs. If memory changes concern you or a loved one, start with a neurologist or primary care clinician. Memory loss deserves a real workup.

Questions Worth Bringing to Your Clinician

If you're weighing any brain-health compound, a short list of questions keeps the conversation useful. Bring these to your next appointment or online intake.

  1. Have my memory changes been properly evaluated, including labs and a cognitive screen?
  2. Could sleep, thyroid, B12, mood or medications be playing a role?
  3. Which options have human trial data for my situation?
  4. What are the known risks of anything I'm considering?
  5. How would we measure whether something is helping?

A good clinician will welcome these questions. If someone skips straight to selling you a vial, that tells you something too.

Interested in Cognitive Peptides? Here's a Safer Starting Point

TelosRX does not offer Dihexa. The human evidence isn't there. If you're curious about peptides studied for focus and stress, consider a provider-reviewed option instead.

Our Semax and Selank nootropic stack is available through an asynchronous online evaluation. These compounded peptides are not FDA-approved. Any prescription is subject to medical approval by a licensed provider, and approval isn't guaranteed.

They aren't Alzheimer's medications, and no one should present them that way. They're an option for adults who want a supervised, pharmacy-sourced route instead of a research-chemical vial.

The Bottom Line on Dihexa for Alzheimer's

  • Rodent studies show memory and synapse effects.
  • The effects appear to run through HGF/MET.
  • No human Dihexa trial has ever been published.
  • A related HGF/MET drug missed its endpoints in a 287-person trial.
  • The long-term safety question around MET signaling is still open.

That's an honest summary of where Dihexa for Alzheimer's stands today. Interesting science. Not a proven option for people.

We'll update this review if a human trial is registered or published. Until then, read bold online claims with healthy skepticism and keep your clinician in the loop.

Frequently Asked Questions

Is Dihexa FDA-approved for Alzheimer's?

No. Dihexa is not FDA-approved for Alzheimer's or any other use. It has never been studied in a published human clinical trial. All of its supporting evidence comes from rat and mouse studies and cell cultures. Products sold online are usually labeled for research use only, not for people.

Has Dihexa been tested in humans?

Not in any published clinical trial. The Alzheimer's Drug Discovery Foundation notes Dihexa has only been studied in rodents and cell culture. A related HGF/MET compound, fosgonimeton, was tested in people with Alzheimer's. It did not meet its primary or secondary endpoints in the LIFT-AD trial.

How is Dihexa supposed to work?

Studies suggest Dihexa binds hepatocyte growth factor and helps it activate its receptor, MET. In the brain, that signaling supports synapses and neuron survival. In rat studies, blocking MET erased Dihexa's effects on memory and dendritic spines. Whether this happens in people hasn't been shown.

What is fosgonimeton, and how is it related to Dihexa?

Fosgonimeton is an injectable HGF/MET positive modulator from the same research lineage as Dihexa. It reached human trials. In LIFT-AD, 287 people with mild-to-moderate Alzheimer's took it or placebo for 26 weeks. The trial missed its primary endpoint, so the pathway remains unproven in humans.

Is Dihexa safe?

Nobody knows yet. There's no published human safety data. A theoretical concern exists because MET signaling is also a growth pathway in some cancers. That risk hasn't been shown, but it hasn't been ruled out. Research-grade products also lack quality controls for purity and dose.

Does TelosRX prescribe Dihexa?

No. TelosRX does not offer Dihexa because the human evidence isn't there. Adults interested in cognitive peptides can explore provider-reviewed options like Semax and Selank. These compounded peptides are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX